The application covers oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.

The provisional patent application describes an oral administration platform intended to deliver fibroblasts and fibroblast-derived therapeutics, including whole cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, to the GI tract using encapsulation materials and enteric coatings engineered to preserve viability and bioactivity during transit.

The disclosed platform contemplates multilayer delivery architectures incorporating hydrogels, nanoparticles, protective intermediate layers, and pH-sensitive outer coatings designed to bypass gastric acid and digestive enzymes before releasing therapeutic payloads in targeted regions of the intestine. The application describes potential oral administration modality across chronic gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, gastritis, Crohn's disease, ulcerative colitis, and gastrointestinal cancers.

Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics commented, "A successful oral fibroblast therapeutic could meaningfully change the treatment paradigm by offering a more accessible, non-invasive approach designed to deliver regenerative and immunomodulatory activity directly to the gastrointestinal tract. We believe this oral platform has the potential to open an entirely new frontier for fibroblast-based medicine."

"What makes this filing especially compelling is the breadth of the therapeutic architecture," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "The application covers not only fibroblasts, but also fibroblast-derived materials, engineered variants, multilayer encapsulation approaches, and programmable release concepts intended to maintain viability and function through oral delivery. From a scientific perspective, this gives us a versatile framework for exploring how fibroblast-based therapeutics may help restore barrier function, modulate inflammation, and support tissue repair in gastrointestinal disease settings."